#AHA25: Amgen’s cholesterol drug cuts first-time cardiovascular events by a quarter
Elizabeth Cairns / endpoints - Amgen on Saturday said its cholesterol-lowering drug Repatha cut cardiovascular events by 25% when added on top of standard therapy in high-risk patients who have never had a heart attack or stroke. Repatha is already ...
AI Summary: At AHA25 in New Orleans, researchers and clinicians showcased pivotal findings – including Amgen’s cholesterol‐lowering drug cutting first‐time cardiovascular events by 25% – while experts like Avirup Guha highlighted innovative cardio‐oncology sessions. The event spotlighted the evolving intersection between heart health and cancer care.
FDA approves J&J’s Darzalex for smoldering multiple myeloma
Lei Lei Wu / endpoints - The FDA on Thursday approved Johnson & Johnson’s Darzalex injection for high-risk smoldering multiple myeloma, a condition in which people have abnormal cells that could turn into myeloma but don’t have ...
AI Summary: The FDA has approved a subcutaneous formulation of daratumumab—marketed as Darzalex—for patients with high‐risk smoldering multiple myeloma, promising a more convenient administration route. This decision is set to improve patient quality of life and streamline treatment protocols in an area of oncology where every minute counts.
Patient in Intellia CRISPR trial dies after being hospitalized with liver injury
Ryan Cross / endpoints - A man in his early 80s who was recently hospitalized with liver injury, a few weeks after receiving an experimental gene editing therapy, died on Wednesday ...
AI Summary: A patient enrolled in an experimental CRISPR gene‐editing trial suffered severe liver injury and later died, spurring renewed scrutiny over the trial’s safety protocols. This fatality casts a long shadow on the promise of gene‐editing therapies, proving that pioneering science can come with perilous risks.
CMS unveils new Medicaid drug payment model
Max Bayer / endpoints - CMS plans to launch a new drug payment model for state Medicaid programs, the first of potentially multiple pricing models under President Donald Trump's "most favored nation" push that the pharma industry has been closely ...
AI Summary: The Centers for Medicare and Medicaid Services has introduced a novel Medicaid drug payment model that employs a most-favored nation pricing strategy, aiming to rein in healthcare spending. This bold move signals a shift toward competitive pricing that, while promising cost efficiencies, also raises eyebrows over its unorthodox approach.
What Trump’s New Drug Pricing Deal Means for People With Obesity
Rebecca Robbins, Dani Blum and Margot Sanger-Katz / nytimes - The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.
AI Summary: In a bold move to tackle the obesity crisis, the Trump administration has brokered agreements with industry giants such as Eli Lilly and Novo Nordisk to slash weight-loss drug prices. The deals, promising reductions as steep as $149 a month, have sparked both applause and debate over the future of drug pricing in America.